Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 1 | $1.04 | $1.24 | $1.14 |
Q2 2025 | 1 | -$0.11 | -$0.09 | -$0.10 |
Q3 2025 | 1 | $1.03 | $1.23 | $1.13 |
Q4 2025 | 1 | -$0.14 | -$0.12 | -$0.13 |
Emergent BioSolutions Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.88. The company had revenue of 293.80 M for the quarter and had revenue of 1.05 B for the year. Emergent BioSolutions Inc. has generated $-15 earnings per share over the last year ($-14.85 diluted earnings per share) and currently has a price-to-earnings ratio of -2.38. Emergent BioSolutions Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | $2.16 | $290.33 M | $293.80 M | ||
08/06/2024 | Q2 2024 | -$5.38 | $190.00 M | $254.70 M | ||
03/30/2024 | Q1 2024 | $0.17 | $300.40 M | |||
03/08/2024 | Q4 2023 | -$0.95 | $276.60 M | |||
12/11/2023 | Q3 2023 | -$0.22 | -$5.13 | -4.91 | $237.43 M | $270.50 M |
08/08/2023 | Q2 2023 | -$5.15 | $216.17 M | $337.90 M | ||
05/09/2023 | Q1 2023 | -$3.65 | $165.10 M | |||
12/11/2023 | Q4 2022 | -$0.22 | -$1.76 | -1.54 | $330.70 M | |
11/08/2022 | Q3 2022 | -$1.52 | $268.30 M | $240.00 M | ||
08/01/2022 | Q2 2022 | -$1.13 | $270.94 M | $242.70 M | ||
04/28/2022 | Q1 2022 | -$0.07 | $307.50 M | |||
02/25/2022 | Q4 2021 | $3.54 | $723.20 M | |||
11/05/2021 | Q3 2021 | -$0.61 | $486.84 M | $329.00 M | ||
07/29/2021 | Q2 2021 | $0.09 | $398.93 M | $397.50 M | ||
04/29/2021 | Q1 2021 | $1.31 | $343.00 M | |||
02/18/2021 | Q4 2020 | $3.51 | $583.00 M | |||
11/05/2020 | Q3 2020 | $0.75 | $437.89 M | $385.20 M | ||
07/31/2020 | Q2 2020 | $1.76 | $294.72 M | $394.70 M | ||
04/30/2020 | Q1 2020 | -$0.24 | $192.50 M | |||
02/24/2020 | Q4 2019 | $0.91 | $360.40 M |
Emergent BioSolutions Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based off last year's report dates.
In the previous quarter, Emergent BioSolutions Inc. (:EBS) reported $1.37 earnings per share (EPS) to beat the analysts' consensus estimate of $0.49 by $0.88.
The conference call for Emergent BioSolutions Inc.'s latest earnings report can be listened to online.
The conference call transcript for Emergent BioSolutions Inc.'s latest earnings report can be read online.
Emergent BioSolutions Inc. (:EBS) has a recorded annual revenue of $1.05 B.
Emergent BioSolutions Inc. (:EBS) has a recorded net income of $1.05 B. Emergent BioSolutions Inc. has generated $-14.85 earnings per share over the last four quarters.
Emergent BioSolutions Inc. (:EBS) has a price-to-earnings ratio of -2.38 and price/earnings-to-growth ratio is -0.04.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED